The Pharmaceutical Market: Australia

Date: January 31, 2013
Pages: 113
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PFCD6640575EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Australia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN AUSTRALIA

The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms.

Headline Expenditure Projections

Pharmaceuticals: AUD12.85bn (US$13.27bn) in 2011 to AUD13.07bn (US$13.59bn) in 2012; +1.6% in local currency terms and +2.4% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with Q412.

Healthcare: AUD122.27bn (US$126.22bn) in 2011 to AUD127.37bn (US$132.47bn) in 2012; +4.2% in local currency terms and +5.0% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with previous quarter.

Medical devices: AUD5.57bn (US$5.75bn) in 2011 to AUD5.82bn (US$6.05bn) in 2012; +4.4% in local currency terms and +5.2% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with Q412.

Risk/Reward Rating: In BMI's Q113 Asia Pacific Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), while Australia's overall RRR score remains 66.2, its ranking has improved from third to second out of the 18 key markets in the region due to the decline in South Korea's RRR. Australia's affluent and increasingly ageing population, coupled with its proper legal framework, will continue to attract pharmaceutical firms to the country. However, profit growth will be limited given that it is a developed market.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Australia Pharmaceuticals And Healthcare Industry SWOT
    Australia Political SWOT
    Australia Economic SWOT
    Australia Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q113
    Rewards
    Risks

AUSTRALIA – MARKET SUMMARY

REGULATORY REGIME

    Table: Summary Of TGA Reforms
    OTC Switching Climate
    Regional Regulatory Harmonisation
    Regulatory Developments
    Intellectual Property Issues
    Trade Agreements
    Pricing And Reimbursement
    Table: Historical PBS Co-Payments
    Price Cuts
    Pricing And Reimbursement Developments
    Table: New PBS Formularies

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Table: Main Causes Of Death In Australia, 2010
    Communicable Diseases
    Table: Percentage Of Children Immunised (December 31 2011)
    Mental Health Issues
    E-Health
    E-Health Developments
    Prescribing Patterns
    Healthcare Sector
    Biotechnology And Research
    Developments In The Biotechnology Sector
    Clinical Trials
    Developments In Clinical Trials
    Medical Device Market
    Table: Medical Device Classifications
    Table: Key Reforms In Medical Device Regulation, 2011

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales, 2008-2016
    Key Growth Factors – Industry
    Table: Overall Healthcare Expenditure, 2008-2016
    Table: Government Healthcare Expenditure, 2008-2016
    Table: Private Healthcare Expenditure, 2008-2016
    Key Growth Factors – Macroeconomic
    Table: Australia Economic Activity, 2011-2016
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales, 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Sales, 2008-2016
    Generic Drug Market Forecast
    Table: Cost Of Selected Drugs Post-Price Disclosure
    Table: Generic Drug Sales, 2008-2016
    OTC Medicine Market Forecast
    Table: OTC Medicine Sales, 2008-2016
    Medical Device Market Forecast
    Table: Medical Device Sales, 2008-2016
    Pharmaceutical Trade Forecast
    Table: Pharmaceutical Exports, 2008-2016
    Table: Pharmaceutical Imports, 2008-2016
    Table: Pharmaceutical Trade Balance, 2008-2016
    Other Healthcare Data Forecasts
    Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

    Pharmaceutical Industry
    Company Developments
    Pharmaceutical Distribution
    Table: Top-20 Pharmaceutical Suppliers By Value From Processed PBS Prescriptions, FY09/10*

COMPANY PROFILES

    Sigma
    Australian Pharmaceutical Industries
    Alphapharm (Mylan)
    Herron Pharmaceuticals
    CSL
    Mayne Pharma Group (Halcygen)
    Sanofi
    GlaxoSmithKline
    Merck & Co
    Novartis
    Table: Australia’s Population By Age Group, 1990-2020 (‘000)
    Table: Australia’s Population By Age Group, 1990-2020 (% of total)
    Table: Australia’s Key Population Ratios, 1990-2020
    Table: Australia’s Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceutical Risk/Reward Ratings Methodology
    Ratings Overview

TABLE: PHARMACEUTICAL RISK/REWARD INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


The Pharmaceutical Market: Singapore US$ 1,295.00 Jan, 2013 · 112 pages
The Pharmaceutical Market: USA US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Cuba US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: Czech Republic US$ 1,295.00 Jan, 2013 · 90 pages
The Pharmaceutical Market: Denmark US$ 1,295.00 Mar, 2013

Ask Your Question

The Pharmaceutical Market: Australia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: